Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) EBITDA: 2010-2025

Historic EBITDA for Arrowhead Pharmaceuticals (ARWR) over the last 16 years, with Sep 2025 value amounting to $31.8 million.

  • Arrowhead Pharmaceuticals' EBITDA rose 110.27% to $17.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $31.8 million, marking a year-over-year increase of 105.29%. This contributed to the annual value of $31.8 million for FY2025, which is 105.29% up from last year.
  • Arrowhead Pharmaceuticals' EBITDA amounted to $31.8 million in FY2025, which was up 105.29% from -$601.7 million recorded in FY2024.
  • In the past 5 years, Arrowhead Pharmaceuticals' EBITDA ranged from a high of $31.8 million in FY2025 and a low of -$601.7 million during FY2024.
  • Over the past 3 years, Arrowhead Pharmaceuticals' median EBITDA value was -$212.4 million (recorded in 2023), while the average stood at -$260.8 million.
  • As far as peak fluctuations go, Arrowhead Pharmaceuticals' EBITDA crashed by 183.35% in 2024, and later skyrocketed by 105.29% in 2025.
  • Arrowhead Pharmaceuticals' EBITDA (Yearly) stood at -$140.9 million in 2021, then decreased by 25.28% to -$176.6 million in 2022, then decreased by 20.28% to -$212.4 million in 2023, then crashed by 183.35% to -$601.7 million in 2024, then spiked by 105.29% to $31.8 million in 2025.